Integra Lifesciences Holdings Corp
IART12.660USD
+0.070+0.56%
Cierre 12/24, 13:00（ET）Cotizaciones retrasadas 15 min
985.39MCap. mercado
PérdidaP/E TTM
Más Datos de Integra Lifesciences Holdings Corp Compañía
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
Información de Integra Lifesciences Holdings Corp
Símbolo de cotizaciónIART
Nombre de la empresaIntegra Lifesciences Holdings Corp
Fecha de salida a bolsaAug 16, 1995
Director ejecutivoPoul (Mojdeh)
Número de empleados4396
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 16
Dirección1100 Campus Road
CiudadPRINCETON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal08540
Teléfono16092750500
Sitio Webhttps://www.integralife.com/
Símbolo de cotizaciónIART
Fecha de salida a bolsaAug 16, 1995
Director ejecutivoPoul (Mojdeh)
Ejecutivos de Integra Lifesciences Holdings Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stuart M. Essig, Ph.D.
Dr. Stuart M. Essig, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
1.59M
-11.20%
Mr. Christian S. (Chris) Schade
Mr. Christian S. (Chris) Schade
Independent Director
Independent Director
90.03K
+41.78%
Dr. Keith Bradley, Ph.D.
Dr. Keith Bradley, Ph.D.
Independent Director
Independent Director
89.14K
+27.45%
Mr. Michael J. Mcbreen
Mr. Michael J. Mcbreen
Executive Vice President, President - Codman Specialty Surgical
Executive Vice President, President - Codman Specialty Surgical
70.34K
+25.21%
Ms. Lea Daniels Knight
Ms. Lea Daniels Knight
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
58.58K
-4.19%
Mr. Jeffrey Mosebrook
Mr. Jeffrey Mosebrook
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
35.79K
-10.69%
Mr. Harvinder Singh
Mr. Harvinder Singh
Executive Vice President, President - International Business
Executive Vice President, President - International Business
21.94K
+65.53%
Ms. Mojdeh Poul
Ms. Mojdeh Poul
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Shaundra D. Clay
Ms. Shaundra D. Clay
Independent Director
Independent Director
--
--
Mr. Chris Ward
Mr. Chris Ward
IR Contact Officer
IR Contact Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stuart M. Essig, Ph.D.
Dr. Stuart M. Essig, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
1.59M
-11.20%
Mr. Christian S. (Chris) Schade
Mr. Christian S. (Chris) Schade
Independent Director
Independent Director
90.03K
+41.78%
Dr. Keith Bradley, Ph.D.
Dr. Keith Bradley, Ph.D.
Independent Director
Independent Director
89.14K
+27.45%
Mr. Michael J. Mcbreen
Mr. Michael J. Mcbreen
Executive Vice President, President - Codman Specialty Surgical
Executive Vice President, President - Codman Specialty Surgical
70.34K
+25.21%
Ms. Lea Daniels Knight
Ms. Lea Daniels Knight
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
58.58K
-4.19%
Mr. Jeffrey Mosebrook
Mr. Jeffrey Mosebrook
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
35.79K
-10.69%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Neurosurgery
208.99M
50.29%
Wound Reconstruction and Care
84.75M
20.39%
Private Label
26.90M
6.47%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
306.31M
73.70%
Asia Pacific
47.73M
11.48%
Europe
42.59M
10.25%
Rest of World
18.97M
4.56%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Neurosurgery
208.99M
50.29%
Wound Reconstruction and Care
84.75M
20.39%
Private Label
26.90M
6.47%
Estadísticas de accionistas
Actualizado: sáb., 15 de nov
Actualizado: sáb., 15 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
11.92%
TRU ST Partnership, L.P.
10.93%
Rubric Capital Management LP
9.83%
The Vanguard Group, Inc.
9.36%
Fuller & Thaler Asset Management Inc.
5.03%
Otro
52.94%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
11.92%
TRU ST Partnership, L.P.
10.93%
Rubric Capital Management LP
9.83%
The Vanguard Group, Inc.
9.36%
Fuller & Thaler Asset Management Inc.
5.03%
Otro
52.94%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
36.53%
Investment Advisor
36.42%
Hedge Fund
18.48%
Corporation
10.93%
Individual Investor
3.20%
Research Firm
2.31%
Pension Fund
1.49%
Bank and Trust
0.44%
Sovereign Wealth Fund
0.04%
Participación institucional
Actualizado: dom., 5 de oct
Actualizado: dom., 5 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
583
73.55M
94.42%
-25.07M
2025Q2
600
89.38M
114.72%
-18.72M
2025Q1
635
87.01M
111.97%
-18.30M
2024Q4
636
81.93M
106.10%
-20.27M
2024Q3
638
82.93M
106.93%
-12.58M
2024Q2
628
84.82M
107.92%
-1.75M
2024Q1
613
79.36M
101.18%
-3.69M
2023Q4
597
79.81M
101.26%
-5.74M
2023Q3
592
81.88M
100.31%
-3.94M
2023Q2
587
82.30M
100.29%
-6.57M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
9.43M
12.11%
-322.52K
-3.31%
Jun 30, 2025
TRU ST Partnership, L.P.
8.52M
10.93%
--
--
Feb 28, 2025
Rubric Capital Management LP
7.35M
9.44%
+2.71M
+58.36%
Jun 30, 2025
The Vanguard Group, Inc.
7.50M
9.63%
+34.14K
+0.46%
Jun 30, 2025
Fuller & Thaler Asset Management Inc.
3.89M
5%
-29.99K
-0.76%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.92M
3.74%
+333.71K
+12.91%
Jun 30, 2025
Invesco Advisers, Inc.
3.18M
4.08%
+51.84K
+1.66%
Jun 30, 2025
State Street Investment Management (US)
2.83M
3.63%
+79.03K
+2.88%
Jun 30, 2025
Boston Management and Research
2.74M
3.52%
--
--
Jun 30, 2025
Paradigm Capital Management, Inc.
2.18M
2.8%
+796.30K
+57.49%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Neuroscience and Healthcare ETF
1.44%
State Street SPDR S&P Health Care Equipment ETF
1.39%
ROBO Global Healthcare Technology & Innovation ETF
1.02%
Invesco S&P SmallCap Health Care ETF
0.49%
Invesco NASDAQ Future Gen 200 ETF
0.43%
Inspire Small/Mid Cap ESG ETF
0.19%
Royce Quant Small-Cap Quality Value ETF
0.13%
Principal U.S. Small-Cap ETF
0.13%
iShares S&P Small-Cap 600 Value ETF
0.12%
State Street SPDR S&P 600 Small Cap Value ETF
0.11%
Ver más
iShares Neuroscience and Healthcare ETF
Proporción1.44%
State Street SPDR S&P Health Care Equipment ETF
Proporción1.39%
ROBO Global Healthcare Technology & Innovation ETF
Proporción1.02%
Invesco S&P SmallCap Health Care ETF
Proporción0.49%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.43%
Inspire Small/Mid Cap ESG ETF
Proporción0.19%
Royce Quant Small-Cap Quality Value ETF
Proporción0.13%
Principal U.S. Small-Cap ETF
Proporción0.13%
iShares S&P Small-Cap 600 Value ETF
Proporción0.12%
State Street SPDR S&P 600 Small Cap Value ETF
Proporción0.11%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Integra Lifesciences Holdings Corp?
Los cinco principales accionistas de Integra Lifesciences Holdings Corp son:
BlackRock Institutional Trust Company, N.A. posee 9.43M acciones, lo que representa el 12.11% del total de acciones.
TRU ST Partnership, L.P. posee 8.52M acciones, lo que representa el 10.93% del total de acciones.
Rubric Capital Management LP posee 7.35M acciones, lo que representa el 9.44% del total de acciones.
The Vanguard Group, Inc. posee 7.50M acciones, lo que representa el 9.63% del total de acciones.
Fuller & Thaler Asset Management Inc. posee 3.89M acciones, lo que representa el 5.00% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 9.43M acciones, lo que representa el 12.11% del total de acciones.
TRU ST Partnership, L.P. posee 8.52M acciones, lo que representa el 10.93% del total de acciones.
Rubric Capital Management LP posee 7.35M acciones, lo que representa el 9.44% del total de acciones.
The Vanguard Group, Inc. posee 7.50M acciones, lo que representa el 9.63% del total de acciones.
Fuller & Thaler Asset Management Inc. posee 3.89M acciones, lo que representa el 5.00% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Integra Lifesciences Holdings Corp?
Los tres principales tipos de accionista de Integra Lifesciences Holdings Corp son:
BlackRock Institutional Trust Company, N.A.
TRU ST Partnership, L.P.
Rubric Capital Management LP
BlackRock Institutional Trust Company, N.A.
TRU ST Partnership, L.P.
Rubric Capital Management LP
¿Cuántas instituciones poseen acciones de Integra Lifesciences Holdings Corp (IART)?
A fecha de 2025Q3, 583 instituciones poseen acciones de Integra Lifesciences Holdings Corp, con un valor de mercado combinado de aproximadamente 73.55M, lo que representa el 94.42% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en -20.30%.
¿Cuál es la mayor fuente de ganancias de Integra Lifesciences Holdings Corp?
El FY2025Q2, el segmento empresarial Neurosurgery generó la ganancia más alta para Integra Lifesciences Holdings Corp, ascendiendo a 208.99M y representando el 50.29% de la ganancia total.
